PRNewsWire
24 Aug 2026, 13:47 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA stated that the benefit-risk assessment for Capricor's lead product candidate, Deramiocel, appears unfavorable due to a lack of evidence of effectiveness. — An unfavorable FDA benefit-risk assessment for a lead product is a critical failure that severely jeopardizes the company's primary path to revenue.
-0.90The FDA rejected Capricor's statistical analysis plan changes as not scientifically justified, labeling the resulting analyses as post-hoc and exploratory. — Regulatory disagreement over data analysis methods suggests flawed trial integrity and increases the likelihood of a BLA rejection.
-0.70Berger Montague has filed a securities fraud class action lawsuit against Capricor Therapeutics on behalf of investors. — Class action lawsuits introduce legal liabilities and management distraction, though they often follow the primary negative news catalyst.
-0.40Which stocks this story touches
Continue reading
6 related stories
Search tags
Facing a securities fraud class action lawsuit following an unfavorable FDA benefit-risk assessment and a 64% share price drop.
The company is the subject of a class action lawsuit.
The company's Board of Directors is under investigation for breach of fiduciary duty.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
5h ago
